Panacea Biotec Limited Bombay S.E.

Equities

PANACEABIO

INE922B01023

Pharmaceuticals

Market Closed - Bombay S.E. 06:10:19 2024-04-16 am EDT 5-day change 1st Jan Change
139.2 INR +1.09% Intraday chart for Panacea Biotec Limited -3.67% -17.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Panacea Biotec Limited Announces the Cessation of Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narasimhan as Independent Directors CI
Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany CI
Panacea Biotec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Panacea Biotec Launches Generic Cancer Treatment Drug in Canada MT
Panacea Biotec's Arm Gets Nine Observations from US FDA MT
Indian Immunologicals targets dengue vaccine launch by Jan 2026 RE
Panacea Biotec Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Panacea Biotec Launches New Pediatric Food, Nutritional Products MT
Panacea Biotec Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Panacea Biotec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Panacea Biotec Limited Reports Earnings Results for the Nine Months Ended December 31, 2022 CI
Panacea Biotec Donates Pentavalent Vaccine to Cuba MT
Panacea Biotec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Chart Panacea Biotec Limited
More charts
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.
More about the company
  1. Stock Market
  2. Equities
  3. PANACEABIO Stock
  4. PANACEABIO Stock
  5. News Panacea Biotec Limited
  6. Panacea Biotec : Supplies More Sputnik V COVID-19 Vaccine in India